Efficacy News and Research

RSS

pSivida resubmits ILUVIEN NDA to FDA for diabetic macular edema treatment

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its licensee, Alimera Sciences, Inc., resubmitted a New Drug Application for the investigational drug ILUVIEN for the treatment of diabetic macular edema (DME) to the U.S. Food and Drug Administration (FDA) on May 12, 2011 to address questions raised in the Complete Response Letter (CRL) Alimera received in December 2010.

16 May 2011

IVF causing multiple birth rates fall

Birth rates for IVF twins and triplets have begun to fall in line with government targets aimed at reducing health risks caused by multiple pregnancies. This fall shows the efficacy of the guidelines brought in by the Human Fertilization and Embryology Authority (HFEA) that urged UK fertility clinics to limit multiple births to no more than 24% in 2009/10. Among naturally-conceived babies, only around one in 70 is a twin.

15 May 2011

AMS signs research grant contract for six sites to evaluate vaginal prolapse repair techniques

American Medical Systems a leading provider of world-class devices and therapies for male and female pelvic health, announced today the signing of a research grant contract for six sites to evaluate anatomical, functional and safety outcomes of two different treatments for vaginal prolapse, Anterior Colporrhaphy, a technique which uses traditional suture plication, versus the Elevate Anterior and Apical Prolapse Repair System.

13 May 2011

German doctors among first to treat ischemic stroke patients with new blood clot retrieval device

Doctors in Germany are among the first to treat ischemic stroke patients outside the United States with the REVIVE SE, a new self-expanding blood clot retrieval and removal device designed to remove blood clots and restore blood flow to the brain in patients having a stroke.

12 May 2011

Bovie Medical first quarter revenues increase 10% to $6.2 million

Bovie Medical Corporation, a manufacturer and marketer of electrosurgical products, today announced its financial results for the first quarter and year ended March 31, 2011.

12 May 2011

New clinical data affirms safety profile of PolyMedix's PMX-30063 in treatment of Staph infections

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, presented new clinical and pre-clinical data related to the safety and efficacy of its novel, lead defensin-mimetic antibiotic, PMX-30063.

12 May 2011

CrystalGenomics receives draft CSR for CG400549 Phase I MAD study in Staph infections

CrystalGenomics, Inc., a biopharmaceutical company with 3 clinical stage candidates, has announced today that the draft Clinical Study Report from CG400549's Phase I Multiple Ascending Dose Study has just been received.

12 May 2011

Sugar boosts effectiveness of first-line antibiotics against chronic bacterial infections

James Collins, a pioneering researcher in the new field of systems biology and a MacArthur Genius, says: "You know the old saying: 'a spoonful of sugar makes the medicine go down?' This is more like 'a spoonful of sugar makes the medicine work.'

12 May 2011

Researcher finds ultrasound as effective as CT scans for head and neck diagnoses

For diagnosing head and neck ailments, tests that use radiation are always less desirable than those that don't. Otolaryngologists have a wide range of techniques available to them, including CT or "CAT" scans, MRI and ultrasound.

12 May 2011

GSK, NanoBio initiate two NB-001 Phase 3 trials in cold sores

NanoBio Corporation today announced the initiation of two Phase 3 multicenter trials evaluating NB-001 as a topical treatment for cold sores, a step forward in their OTC licensing agreement with GlaxoSmithKline Consumer Healthcare.

12 May 2011

MHI team uses cryoablation to successfully treat atrial fibrillation

The electrophysiology team at the Montreal Heart Institute (MHI) used cryoablation (ablation using cold) to treat a patient suffering from atrial fibrillation, the most common form of cardiac arrhythmia, and one associated with significant morbidity.

From Medtronic 11 May 2011

Naurex announces completion of $18 million Series A financing

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the completion of an $18 million Series A financing led by Adams Street Partners and Latterell Venture Partners.

11 May 2011

TSA, Psyadon Pharmaceuticals partner for ecopipam clinical trial in Tourette Syndrome

The national Tourette Syndrome Association and Psyadon Pharmaceuticals Inc. are pleased to announce their collaboration on a clinical trial to determine the potential efficacy of a novel drug, ecopipam, for managing the symptoms of the neurological disorder Tourette Syndrome.

11 May 2011

Pacira Pharmaceuticals reports net loss of $9.8 million for first quarter 2011

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2011, provided an update on the execution of its pre-commercial and launch strategies for EXPAREL, and reiterated 2011 financial guidance.

11 May 2011

GATTEX Phase 3 study results in adult short bowel syndrome presented at DDW 2011

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced that GATTEX, a novel, recombinant analog of human glucagon-like peptide 2, was found to effectively and safely reduce parenteral support volume in adult short bowel syndrome-intestinal failure patients.

11 May 2011

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

UCB announced today results from a post hoc analysis of the RAPID 1 study published in the Journal of Rheumatology. The results suggest moderate to severe rheumatoid arthritis patients treated with Cimzia, the only approved PEGylated anti-TNF, together with methotrexate, achieved a rapid response associated with improved long-term outcomes one year after treatment began.

11 May 2011

Adherence to disease-modifying drugs is low in patients with multiple sclerosis

Disease-modifying drugs (DMDs) are injected medications used to slow the progression of multiple sclerosis, and have been shown to reduce the frequency and severity of relapses. But according to a new study led by St. Michael's Hospital and the Institute for Clinical Evaluative Sciences, adherence to all DMDs is low, with less than half of patients, or 44 per cent, continually adherent after two years.

11 May 2011

3M introduces Clean-Trace Hygiene Management System for healthcare facilities

As part of its effort to offer a wide range of environmental hygiene solutions for healthcare facilities, 3M Infection Prevention today announced its 3M™ Clean-Trace™ Hygiene Management System. This solution is designed to help hospitals assess the cleanliness of a surface and validate the efficacy of cleaning protocols and worker performance in less than one minute

11 May 2011

Dalbavancin surveillance antibiotic results for Gram-positive pathogens presented at ECCMID meeting

Durata Therapeutics today announced surveillance data demonstrating potency of the Company's lead antibiotic product, dalbavancin, a long-acting, intravenous lipoglycopeptide, against a broad spectrum of gram-positive bacteria prevalent in recent years.

10 May 2011

Insmed first quarter revenues decrease to $1.6 million

Insmed Incorporated, a biopharmaceutical company, today reported results for the first quarter ended March 31, 2011.

10 May 2011

Efficacy News and Research

pSivida resubmits ILUVIEN NDA to FDA for diabetic macular edema treatment

IVF causing multiple birth rates fall

AMS signs research grant contract for six sites to evaluate vaginal prolapse repair techniques

German doctors among first to treat ischemic stroke patients with new blood clot retrieval device

Bovie Medical first quarter revenues increase 10% to $6.2 million

New clinical data affirms safety profile of PolyMedix's PMX-30063 in treatment of Staph infections

CrystalGenomics receives draft CSR for CG400549 Phase I MAD study in Staph infections

Sugar boosts effectiveness of first-line antibiotics against chronic bacterial infections

Researcher finds ultrasound as effective as CT scans for head and neck diagnoses

GSK, NanoBio initiate two NB-001 Phase 3 trials in cold sores

MHI team uses cryoablation to successfully treat atrial fibrillation

Naurex announces completion of $18 million Series A financing

TSA, Psyadon Pharmaceuticals partner for ecopipam clinical trial in Tourette Syndrome

Pacira Pharmaceuticals reports net loss of $9.8 million for first quarter 2011

GATTEX Phase 3 study results in adult short bowel syndrome presented at DDW 2011

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

Adherence to disease-modifying drugs is low in patients with multiple sclerosis

3M introduces Clean-Trace Hygiene Management System for healthcare facilities

Dalbavancin surveillance antibiotic results for Gram-positive pathogens presented at ECCMID meeting

Insmed first quarter revenues decrease to $1.6 million

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News